# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
EVERSANA to provide integrated commercialization services, enhancing launch readiness and market entry for differentiated Cutan...
Exclusive relationship through Named Patient Programs establishes footprint in Greece, Cyprus and additional Balkan countriesCR...
Maxim Group analyst Michael Okunewitch upgrades Citius Oncology (NASDAQ:CTOR) from Hold to Buy and announces $6 price target.
Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc...
Proprietary model informs targeted sales and marketing strategies with feedback loop thataugments precision and impact of targe...
Citius Oncology (NASDAQ:CTOR) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.1...